To give a little insight into the greed of our friends in the pharmaceutical industry, consider that it is generally legal for drug manufacturers to pay generic drug manufacturers to not manufacture generic copies of their medications, even as patents set to expire.
From the latest New England Journal of Medicine:
The case offers a rare glimpse of the high-stakes arrangements through which pharmaceutical companies delay sales of generics and keep drug prices high — all under the watchful eyes of the Federal Trade Commission (FTC) and the Department of Justice. Though the cash payments at the heart of this deal are shocking, such "reverse payments" from a brand-name drug producer to a generics company are not illegal. What's unusual about the case isn't the millions promised to Apotex, it's that the settlement fell apart and generic clopidogrel was released for sale. In recent years, such settlements have generally stuck, despite federal authorities' efforts to undo them, and generics have been kept off the market.”
The article goes on to describe that these arrangements are relatively common and end up costing consumers a fortune.
For much more on this topic, interested readers can do a quick search on PharmaGossip. There are dozens of relevant posts.